Literature DB >> 15300179

Determinants of regional myocardial acidosis during cardiac surgery.

Dharam J Kumbhani1, Nancy A Healey, Vladimir Birjiniuk, Michael D Crittenden, Miguel Josa, Patrick R Treanor, Shukri F Khuri.   

Abstract

BACKGROUND: Intraoperative regional myocardial acidosis (RMA) during cardiac surgery has been shown to be reflective of regional myocardial ischemia and an independent predictor of adverse postoperative outcomes. This study identifies the determinants of intraoperative RMA.
METHODS: Intramyocardial tissue pH(37C) in the anterior and posterior LV walls was measured in 641 adult patients during cardiac surgery. RMA at two intraoperative periods was quantified as integrated mean pH(37C) < 6.35 during aortic clamping (AC) and pH(37C) < 6.73 at the end of cardiopulmonary bypass (CPB). These pH thresholds were chosen because of their demonstrated relationship to long-term patient survival. Multivariate logistic regression models were constructed. An acidosis prediction score was constructed based on the factors determining RMA at the end of CPB.
RESULTS: Independent determinants of RMA during AC were preoperative New York Heart Association class III/IV (P = .007), current smoker (P = .0088), pH(37C) < 6.63 prior to AC (P < .0001), and intraoperative myocardial management technique (P = .0001). Independent determinants of RMA at end of CPB were ASA class IV/V (P = .0042), pH(37C) < 6.63 prior to AC (P = .035), pH(37C) < 6.35 during AC (P = .001), and total duration of CPB > or = 212 minutes (P = .001).
CONCLUSIONS: RMA during cardiac surgery is determined by patient risk factors, the magnitude of preceding regional myocardial acidosis, and the duration of CPB. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15300179     DOI: 10.1016/j.surg.2004.04.015

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium.

Authors:  Jessica C Garbern; Elina Minami; Patrick S Stayton; Charles E Murry
Journal:  Biomaterials       Date:  2010-12-24       Impact factor: 12.479

2.  Tunable protein release from acetalated dextran microparticles: a platform for delivery of protein therapeutics to the heart post-MI.

Authors:  Sophia Suarez; Gregory N Grover; Rebecca L Braden; Karen L Christman; Adah Almutairi
Journal:  Biomacromolecules       Date:  2013-10-16       Impact factor: 6.988

Review 3.  Environmentally responsive hydrogels for repair of cardiovascular tissue.

Authors:  Shuaimeng Guan; Jiankang Li; Kun Zhang; Jingan Li
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

4.  Degradable acetalated dextran microparticles for tunable release of an engineered hepatocyte growth factor fragment.

Authors:  Sophia L Suarez; Adam Muñoz; Aaron Mitchell; Rebecca L Braden; Colin Luo; Jennifer R Cochran; Adah Almutairi; Karen L Christman
Journal:  ACS Biomater Sci Eng       Date:  2015-12-14

5.  Coronary bypass grafting using crossclamp fibrillation does not result in reliable reperfusion of the myocardium when the crossclamp is intermittently released: a prospective cohort study.

Authors:  Joel Dunning; Steven Hunter; Simon W H Kendall; John Wallis; W Andrew Owens
Journal:  J Cardiothorac Surg       Date:  2006-11-21       Impact factor: 1.637

Review 6.  Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases.

Authors:  Xiaoshan Liao; Xushan Yang; Hong Deng; Yuting Hao; Lianzhi Mao; Rongjun Zhang; Wenzhen Liao; Miaomiao Yuan
Journal:  Front Bioeng Biotechnol       Date:  2020-03-31

7.  Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs.

Authors:  Yan Li; Xin Chen; Ronghua Jin; Lu Chen; Ming Dang; Hao Cao; Yun Dong; Bolei Cai; Guo Bai; J Justin Gooding; Shiyu Liu; Duohong Zou; Zhiyuan Zhang; Chi Yang
Journal:  Sci Adv       Date:  2021-02-24       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.